Nurse Practitioner in St. Charles, IL Accepting Medicare
1 Nurse Practitioner nurses found. Showing 1 - 1
 Shelly Sinatra, CNP Nurse Practitioner - Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3310 W. Main St, Suite 200, St. Charles, IL 60175 Phone: 630-897-6044 Fax: 630-897-0180 |
News Archive
FDA approves protocol for Medtronic's SYMPLICITY HTN-3 for treatment of hypertension
Medtronic, Inc., announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY HTN-3, the company's U.S. clinical trial of renal denervation with the Symplicity Catheter System for the treatment of resistant hypertension, an especially dangerous disease affecting hundreds of millions of people worldwide.
Study aims to understand spaces in which young people engage in sex after alcohol use
A study conducted by Columbia Mailman School of Public Health and the Muhimbili University of Health and Allied Sciences in Tanzania sheds light on the factors that influence young people's access to and use of alcohol, and subsequent engagement in safe or unsafe sexual behaviors.
Researchers one step closer to developing new treatment strategy to combat TB
By uncovering the 3-dimensional structure of an enzyme that is critical for the survival of the bacterium that cause tuberculosis, researchers may be one step closer to developing a new strategy to combat TB infections.
Medicare cuts looming for doctors; Debt panel's health suggestions questioned
"The scheduled cuts [to doctors' reimbursements from Medicare] - the result of a failed system set up years ago to control costs - have raised alarms that real damage to Medicare could result if the lame-duck Congress winds up in a partisan standoff and fails to act by Dec. 1. That's when an initial 23 percent reduction would hit. ... Doctors have muddled through with temporary reprieves for years. ... there's no agreement among lawmakers and the Obama administration on how long a reprieve to grant or whether the cost - about $1 billion per month - should be added to the deficit or paid for with spending reductions elsewhere" (Alonso-Zaldivar, 11/13).
Onyx announces results from regorafenib Phase 3 trial on GIST
Onyx Pharmaceuticals, Inc. today announced results from the Phase 3 trial GRID (GIST – Regorafenib in Progressive Disease) evaluating the investigational compound regorafenib (BAY 73-4506), a Bayer-owned compound, for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.
› Verified 5 days ago